Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine

Highlights • BDNF level is a potential biomarker toward response to antidepressants. • Major depressive disorder (MDD) was treated with fluoxetine or desvenlafaxine. • Randomized, open-label study assessed efficacy, safety and plasma BDNF levels. • Both medicines comparably improved HAM-D scores and...

Full description

Saved in:
Bibliographic Details
Published in:Asian journal of psychiatry 2015-12, Vol.18, p.37-41
Main Authors: Ghosh, R, Gupta, R, Bhatia, M.S, Tripathi, A.K, Gupta, L.K
Format: Article
Language:English
Subjects:
Adult
Antidepressive Agents - administration & dosage
Antidepressive Agents - adverse effects
BDNF
Brain-Derived Neurotrophic Factor - metabolism
Depression
Depressive Disorder, Major - diagnosis
Depressive Disorder, Major - drug therapy
Depressive Disorder, Major - metabolism
Depressive Disorder, Major - psychology
Desvenlafaxine
Desvenlafaxine Succinate - administration & dosage
Desvenlafaxine Succinate - adverse effects
Diagnostic and Statistical Manual of Mental Disorders
Drug Monitoring - methods
Female
Fluoxetine
Fluoxetine - administration & dosage
Fluoxetine - adverse effects
Humans
Internal Medicine
Male
MDD
Middle Aged
Open label
Prognosis
Psychiatric Status Rating Scales
Psychiatry
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • BDNF level is a potential biomarker toward response to antidepressants. • Major depressive disorder (MDD) was treated with fluoxetine or desvenlafaxine. • Randomized, open-label study assessed efficacy, safety and plasma BDNF levels. • Both medicines comparably improved HAM-D scores and tolerated well in depression. • Both the antidepressant agents significantly increased BDNF levels.
ISSN:1876-2018
1876-2026
DOI:10.1016/j.ajp.2015.10.006